Free Trial

Sera Prognostics Q4 2023 Earnings Report

Sera Prognostics logo
$4.12 -0.15 (-3.51%)
As of 02/21/2025 04:00 PM Eastern

Sera Prognostics EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.25
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Sera Prognostics Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
$0.10 million
Beat/Miss
Missed by -$60.00 thousand
YoY Revenue Growth
N/A

Sera Prognostics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Sera Prognostics Earnings Headlines

9/9 on TSLA from June to January
Please take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!
Sera Prognostics CFO sells $27,090 in stock
Sera Prognostics CEO sells $64,463 in stock
See More Sera Prognostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sera Prognostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sera Prognostics and other key companies, straight to your email.

About Sera Prognostics

Sera Prognostics (NASDAQ:SERA), a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

View Sera Prognostics Profile

More Earnings Resources from MarketBeat